Chemical & Engineering News Feature: "Can Amylin Weight-Loss Drugs Compete in a World of GLP-1s?"
C&EN published a comprehensive April 2026 feature examining whether amylin analogs — Novo's cagrilintide, Lilly's eloralintide, and Roche/Zealand's petrelintide — can carve meaningful share in a market dominated by semaglutide and tirzepatide. Wall Street initially expected amylin candidates to differentiate on muscle preservation and reduced GI side effects, but as Phase 2 readouts arrive investor enthusiasm has cooled. CagriSema Phase 3 head-to-head against tirzepatide is the make-or-break readout for Novo Nordisk's amylin strategy.